Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Liabilities: 2019-2024

Historic Total Liabilities for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $2.4 billion.

  • BridgeBio Pharma's Total Liabilities rose 55.09% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 55.09%. This contributed to the annual value of $2.4 billion for FY2024, which is 25.84% up from last year.
  • As of FY2024, BridgeBio Pharma's Total Liabilities stood at $2.4 billion, which was up 25.84% from $1.9 billion recorded in FY2023.
  • BridgeBio Pharma's Total Liabilities' 5-year high stood at $2.4 billion during FY2024, with a 5-year trough of $595.7 million in FY2020.
  • Its 3-year average for Total Liabilities is $2.0 billion, with a median of $1.9 billion in 2023.
  • In the last 5 years, BridgeBio Pharma's Total Liabilities soared by 282.59% in 2020 and then decreased by 0.55% in 2022.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Total Liabilities stood at $595.7 million in 2020, then spiked by 215.32% to $1.9 billion in 2021, then dropped by 0.55% to $1.9 billion in 2022, then climbed by 1.12% to $1.9 billion in 2023, then rose by 25.84% to $2.4 billion in 2024.